Skip to main content
SpringerLink
Log in

Usefulness of[111In-DTPA0] octreotide scintigraphy in a family with von Hippel-Lindau disease

  • Case Report
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

The identification of patients with von Hippel-Lindau (VHL) disease dictates accurate genetic counseling of family members, whereas screening for early detection of visceral and neurological involvement is usually performed by a combination of radiological and nuclear medicine techniques such as ultrasonography or contrastenhanced computed tomography of the upper abdomen, magnetic resonance imaging of the central nervous system and 131I-metaiodobenzylguanidine-scintigraphy. The role of 111-indium-diethylenetriaminepentaacetic acid [111ln-DTPA0] octreotide scintigraphy in this clinical context has never been investigated. Here, we report imaging findings in a VHL patient and in 3 consecutive family members undergoing clinical and radiological screening that included [111ln-DTPA0] octreotide scintigraphy in addition to the above-mentioned procedures. Somatostatin receptor expression was investigated in vitro by immunohistochemistry in pancreatic tumor sections. On the basis of in vivo and in vitro findings, octreotide long-acting release treatment followed by 90Y-1,4,7,10-Tetraazacyclododecane-N, N′, N′’, N‴-tetraacetic acid (DOTA0)-Tyr3-octreotide led to a lack of progression in this patient although this result is a possibility which needs to be proved by further investigation and longer follow-up. The results of this study suggest that [111In-DTPA0] octreotide scintigraphy may be helpful in the routine work-up of VHL patients for diagnostic and therapeutic purposes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Maher ER, Iselius L, Yates JR, et al. Von Hippel-Lindau disease: a genetic study. J Med Genet 1991, 28: 443–7.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  2. Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993, 260: 1317–20.

    Article  PubMed  CAS  Google Scholar 

  3. Ong KR, Woodward ER, Killick P, Lim C, Macdonald F, Maher ER. Genotype-phenotype correlations in von Hippel-Lindau disease. Hum Mutat 2007, 28: 143–9.

    Article  PubMed  CAS  Google Scholar 

  4. Weirich G, Klein B, Wohl T, Engelhardt D, Brauch H. VHL2C phenotype in a german von Hippel-Lindau family with concurrent VHL gemline mutations P81S and L188V. J Clin Endocrinol Metab 2002, 87: 5241–6.

    Article  PubMed  CAS  Google Scholar 

  5. Choyke PL, Glenn GM, Walther MM, Patronas NJ, Linehan WM, Zbar B. von Hippel-Lindau disease: genetic, clinical and imaging features. Radiology 1995, 194: 629–42.

    PubMed  CAS  Google Scholar 

  6. Choyke PL, Filling-Katz MR, Shawker TH, et al. von Hippel-Lindau disease: radiologic screening for visceral manifestations. Radiology 1990, 174: 815–20.

    PubMed  CAS  Google Scholar 

  7. Janson ET, Oberg K. Neuroendocrine tumors—somatostatin receptor expression and somatostatin analog treatment. Cancer Chemother Biol Response Modif 2003, 21: 535–46.

    Article  PubMed  CAS  Google Scholar 

  8. Duet M, Sauvaget E, Pételle B, et al. Clinical impact of somatostatin receptor scintigraphy in the management of paragangliomas of the head and neck. J Nucl Med 2003, 44: 1767–74.

    PubMed  Google Scholar 

  9. Kaltsas G, Rockall A, Papadogias D, Reznek R, Grossman AB. Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours. Eur J Endocrinol 2004, 151: 15–27.

    Article  PubMed  CAS  Google Scholar 

  10. Duet M,Guichard JP, Rizzo N, Boudiaf M, Herman P, Tran Ba Huy P. Are somatostatin analogs therapeutic alternatives in the management of head and neck paragangliomas? Laryngoscope 2005, 115: 1381–4.

    Article  PubMed  CAS  Google Scholar 

  11. Shojamanesh H, Gibril F, Louie A, et al. Prospective study of the antitumor efficacy of longterm octreotide treatment in patients with progressive metastatic gastrinoma. Cancer 2002, 94: 331–43.

    Article  PubMed  CAS  Google Scholar 

  12. Bodei L, Cremonesi M, Grana C, et al. Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2004, 31: 1038–46.

    Article  PubMed  CAS  Google Scholar 

  13. Waldherr C, Pless M, Maecke HR, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq 90Y-DOTATOC. J Nucl Med 2002, 43: 610–6.

    PubMed  CAS  Google Scholar 

  14. Libutti SK, Choyke PL, Bartlett DL, et al. Pancreatic neuroendocrine tumors associated with von Hippel Lindau diseases: diagnostic and management recommendations. Surgery 1998, 124: 1153–9.

    Article  PubMed  CAS  Google Scholar 

  15. Ferone D, van Hagen MP, Kwekkeboom DJ, et al. Somatostatin receptor subtypes in human thymoma and inhibition of cell proliferation by octreotide in vitro. J Clin Endocrinol Metab 2000, 85: 1719–26.

    Article  PubMed  CAS  Google Scholar 

  16. Heppeler A, Froidevaux S, Mäcke HR, et al. Radiometallabelled macrocyclic chelator-derivatised somatostatin analogue with superb tumour-targeting properties and potential for receptor-mediated internal radiotherapy. Chem Eur J 1999, 5: 1016–23.

    Article  Google Scholar 

  17. Chinol M, Bodei L, Cremonesi M, Paganelli G. Receptormediated radiotherapy with 90YDOTA-D-Phe1-Tyr3-octreotide: the experience of the European Institute of Oncology group. Semin Nucl Med 2002, 32: 141–7.

    Article  PubMed  Google Scholar 

  18. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981, 47: 207–14.

    Article  PubMed  CAS  Google Scholar 

  19. Camera L, Biondi B, Daniele S, et al. Screening in von Hippel-Lindau disease: concurrent pheochromocytomas, paragangliomas and spinal hemangioblastomas revealed by helical-CT, MIBG scintigraphy and MRI in an asymptomatic patient. European Journal of Radiology Extra 2003, 48: 8–13.

    Article  Google Scholar 

  20. Opocher G, Conton P, Schiavi F, Macino B, Mantero F. Pheochromocytoma in von Hippel-Lindau disease and neurofibromatosis type 1. Fam Cancer 2005, 4: 13–6.

    Article  PubMed  Google Scholar 

  21. Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet 2005, 366: 665–75.

    Article  PubMed  Google Scholar 

  22. Neumann HP, Bausch B, McWhinney SR, et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 2002,346: 1459–66.

    Article  PubMed  CAS  Google Scholar 

  23. Hoefnagel CA. Metaiodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumours. Eur J Nucl Med 1994, 25: 561–81.

    Google Scholar 

  24. Tenenbaum F, Lumbroso J, Schlumberger M, et al. Comparison of radiolabeled octreotide and meta-iodoben-zylguanidine (MIBG) scintigraphy in malignant pheochromocytoma. J Nucl Med 1995, 36: 1–6.

    PubMed  CAS  Google Scholar 

  25. van der Harst E, de Herder W, Bruining HA, et al. 123I-Metaiodobenzylguanidine and 111In-Octreotide uptake in benign and malignant pheochromocytomas. J Clin Endocrinol Metab 2001, 86: 685–93.

    PubMed  Google Scholar 

  26. Kwekkeboom DJ, van Urk H, Pauw BK, et al. Octreotide scintigraphy for the detection of paragangliomas. J Nucl Med 1993, 34: 873–8.

    PubMed  CAS  Google Scholar 

  27. Schmidt M, Fischer E, Dietlein M, et al. Clinical value of somatostatin receptor imaging in patients with suspected head and neck paragangliomas. Eur J Nucl Med Mol Imaging 2002, 29: 1571–80.

    Article  PubMed  CAS  Google Scholar 

  28. Hofland LJ, Lamberts SW. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 2003, 24: 28–47.

    Article  PubMed  CAS  Google Scholar 

  29. Mukhopadhyay B, Sahdev A, Monson JP, Besser GM, Reznek RH, Chew SL. Pancreatic lesions in von Hippel-Lindau disease. Clin Endocrinol (Oxf) 2002, 57: 603–8.

    Article  CAS  Google Scholar 

  30. Lamberts SW, Hofland LJ, van Koetsveld PM, et al. Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors: consequences with regard to diagnosis, localisation and therapy. J Clin Endocrinol Metab 1990, 71: 566–74.

    Article  PubMed  CAS  Google Scholar 

  31. Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123l-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993, 20: 716–31.

    Article  PubMed  CAS  Google Scholar 

  32. Chiti A, Fanti S, Savelli G, Romeo A, et al. Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours. Eur J Nucl Med 1998, 25: 1396–403.

    Article  PubMed  CAS  Google Scholar 

  33. Lamberts SW, Hofland LJ, Lely AJ, De Herder WW. Somastatin receptor expression in multiple endocrine neoplasia and in von Hippel-Lindau disease. J Intern Med 1998, 243: 569–71.

    Article  PubMed  CAS  Google Scholar 

  34. Reubi JC, Waser B, Laissue JA, Gebbers JO. Somatostatin and vasoactive intestinal peptide receptors in human mesenchymal tumours: in vitro identification. Cancer Res 1992, 56: 1922–31.

    Google Scholar 

  35. Reubi JC, Kvols L. Somatostatin receptors in human renal cell carcinomas. Cancer Res 1992, 52: 6074–8.

    PubMed  CAS  Google Scholar 

  36. Eriksson B, Oberg K. Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook. Ann Oncol 1999, 10 (Suppl 2): S31–8.

    Article  PubMed  Google Scholar 

  37. Kvols LK, Moertel CG, O’Connell MJ, Schutt AJ, Rubin J, Hahn RG. Treatment of malignant carcinoid syndrome, evaluation of a long-acting somatostatin analogue. N Engl J Med 1986 315: 663–6.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical and Molecular Endocrinology and Oncology, Italy

    M. Pulcrano MD, L. Pagano, A. Colao, G. Lombardi & B. Biondi

  2. Department of Biomorphological and Functional Sciences, Federico II University of Naples, Naples

    L. Camera, S. Del Vecchio, L. Pace, G. Storto & M. Salvatore

  3. Department of Endocrinological and Metabolic Sciences (DISEM), University of Genoa, Genoa

    D. Ferone

  4. Department of Nuclear Medicine, European Institute of Oncology, Milan

    L. Bodei & G. Paganelli

  5. Department of Endocrinology and Medical and Surgical Sciences, University of Padua Medical, School, Padua, Italy

    A. Murgia

Authors
  1. M. Pulcrano MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. Camera
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L. Pagano
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. Del Vecchio
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D. Ferone
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. L. Bodei
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. Murgia
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. L. Pace
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. G. Storto
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. G. Paganelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. A. Colao
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. M. Salvatore
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. G. Lombardi
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. B. Biondi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Pulcrano MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pulcrano, M., Camera, L., Pagano, L. et al. Usefulness of[111In-DTPA0] octreotide scintigraphy in a family with von Hippel-Lindau disease. J Endocrinol Invest 31, 352–359 (2008). https://doi.org/10.1007/BF03346370

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03346370

Key-words

Search

Navigation